Everest Medicines

Ver el organigrama con sus 15 ejecutivos principales

Biografías más buscadas en Everest Medicines

• Yongqing Luo, Executive Director and Chief Executive Officer
• Wei Fu, Chairman of the Board
• Shidong Jiang, Independent Non-Executive Directors

Recientes movimientos de ejecutivos en Everest Medicines

• Sandra Zeng, se ha incorporado a la empresa como Chief Medical Officer  (noticia publicada el 18 de marzo de 2024).
• Rico Liang, se ha incorporado a la empresa como Chief Product Officer  (noticia publicada el 18 de marzo de 2024).
• Lan Kang, Director, ha dejado la empresa  (noticia publicada el 14 de enero de 2024).

Haga clic aquí para ver otros movimientos en Everest Medicines

Crear su alerta
para seguir los movimientos de los ejecutivos en Everest Medicines.

Everest Medicines tiene 1.869 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacia

• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado el 23 de marzo de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado el 19 de marzo de 2024).
• Frontier Medicines acaba de anunciar una recaudación de fondos de 80 millones de dólares. (publicado el 27 de febrero de 2024).

Otros contactos sugeridos en el sector Farmacia

• Jean-Frédéric Paulsen - Executive Chairman of the Board en Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director en Dirk Rossmann
• Thierry Abribat - Chief Executive Officer en Amolyt Pharma

Saber más sobre el sector Farmacia >

Últimos comunicados de prensa de Everest Medicines

• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 – Everest Medicines
• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 – Everest Medicines
• Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer – Everest Medicines
• Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients – Everest Medicines
• Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® – Everest Medicines
• Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer – Everest Medicines
• Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients – Everest Medicines
• Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® – Everest Medicines
• Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 – Everest Medicines
• Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau – Everest Medicines
• View more press releases Close

Redes sociales sobre Everest Medicines

• Everest Medicines en Wikipedia, Google News y Yahoo Finance
• Everest Medicines en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Yifan Li

Llame a Everest Medicines al +1 203...

Ver el organigrama

Register to receive your alert

Señalar un error